Immix Biopharma (IMMX) Competitors $2.54 +0.03 (+1.20%) Closing price 04:00 PM EasternExtended Trading$2.53 -0.01 (-0.24%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMX vs. HRTX, AVIR, TLSA, PRQR, SGMT, ENTA, TRDA, EPRX, BIOA, and BDTXShould you be buying Immix Biopharma stock or one of its competitors? The main competitors of Immix Biopharma include Heron Therapeutics (HRTX), Atea Pharmaceuticals (AVIR), Tiziana Life Sciences (TLSA), ProQR Therapeutics (PRQR), Sagimet Biosciences (SGMT), Enanta Pharmaceuticals (ENTA), Entrada Therapeutics (TRDA), Eupraxia Pharmaceuticals (EPRX), BioAge Labs (BIOA), and Black Diamond Therapeutics (BDTX). These companies are all part of the "pharmaceutical products" industry. Immix Biopharma vs. Its Competitors Heron Therapeutics Atea Pharmaceuticals Tiziana Life Sciences ProQR Therapeutics Sagimet Biosciences Enanta Pharmaceuticals Entrada Therapeutics Eupraxia Pharmaceuticals BioAge Labs Black Diamond Therapeutics Immix Biopharma (NASDAQ:IMMX) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership. Do insiders and institutionals have more ownership in IMMX or HRTX? 11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 55.4% of Immix Biopharma shares are held by insiders. Comparatively, 5.9% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer IMMX or HRTX? In the previous week, Immix Biopharma had 3 more articles in the media than Heron Therapeutics. MarketBeat recorded 3 mentions for Immix Biopharma and 0 mentions for Heron Therapeutics. Immix Biopharma's average media sentiment score of 0.89 beat Heron Therapeutics' score of 0.00 indicating that Immix Biopharma is being referred to more favorably in the media. Company Overall Sentiment Immix Biopharma Positive Heron Therapeutics Neutral Which has more volatility and risk, IMMX or HRTX? Immix Biopharma has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Do analysts prefer IMMX or HRTX? Immix Biopharma currently has a consensus price target of $8.00, suggesting a potential upside of 214.96%. Heron Therapeutics has a consensus price target of $4.50, suggesting a potential upside of 233.33%. Given Heron Therapeutics' higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than Immix Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immix Biopharma 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Heron Therapeutics 2 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is IMMX or HRTX more profitable? Immix Biopharma has a net margin of 0.00% compared to Heron Therapeutics' net margin of -0.62%. Heron Therapeutics' return on equity of 0.00% beat Immix Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Immix BiopharmaN/A -205.35% -110.63% Heron Therapeutics -0.62%N/A -0.40% Which has better valuation & earnings, IMMX or HRTX? Heron Therapeutics has higher revenue and earnings than Immix Biopharma. Heron Therapeutics is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmix BiopharmaN/AN/A-$21.61M-$0.77-3.30Heron Therapeutics$144.29M1.72-$13.58M-$0.02-67.50 SummaryHeron Therapeutics beats Immix Biopharma on 9 of the 14 factors compared between the two stocks. Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMX vs. The Competition Export to ExcelMetricImmix BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$72.37M$3.35B$6.11B$10.56BDividend YieldN/A2.29%5.69%4.75%P/E Ratio-3.3021.5785.4827.60Price / SalesN/A476.51624.19239.62Price / CashN/A47.1237.9261.55Price / Book5.2910.1413.136.76Net Income-$21.61M-$52.31M$3.30B$275.88M7 Day Performance22.12%6.72%5.29%3.72%1 Month Performance17.05%15.01%9.94%10.22%1 Year Performance66.01%29.34%87.78%35.86% Immix Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMXImmix Biopharma3.4048 of 5 stars$2.54+1.2%$8.00+215.0%+73.1%$72.37MN/A-3.309Analyst ForecastHigh Trading VolumeHRTXHeron Therapeutics3.5563 of 5 stars$1.25-0.8%$4.50+260.0%-32.7%$229.15M$144.29M-62.50300Positive NewsAnalyst ForecastAVIRAtea Pharmaceuticals1.9288 of 5 stars$2.88-0.7%$6.00+108.3%-12.9%$228.55MN/A-1.7970News CoverageAnalyst ForecastTLSATiziana Life Sciences0.2456 of 5 stars$1.95-9.7%N/A+135.4%$227.85MN/A0.008Upcoming EarningsAnalyst ForecastGap UpPRQRProQR Therapeutics2.2988 of 5 stars$2.16+1.4%$8.00+270.4%+16.4%$227.26M$16.49M-4.70180News CoveragePositive NewsAnalyst ForecastSGMTSagimet Biosciences2.8689 of 5 stars$6.98+1.7%$25.67+267.7%+76.4%$227.00MN/A-3.818News CoverageAnalyst ForecastENTAEnanta Pharmaceuticals4.0611 of 5 stars$10.61-11.4%$20.83+96.4%-4.1%$226.84M$67.64M-2.46160Analyst ForecastHigh Trading VolumeTRDAEntrada Therapeutics3.1239 of 5 stars$5.88+1.4%$25.67+336.5%-64.6%$223.68M$210.78M-3.30110Positive NewsAnalyst ForecastEPRXEupraxia Pharmaceuticals2.8545 of 5 stars$6.07+2.9%$11.00+81.2%+141.8%$218.28MN/A-7.1429Analyst ForecastAnalyst RevisionHigh Trading VolumeBIOABioAge Labs0.1863 of 5 stars$5.92+0.7%N/AN/A$212.23MN/A0.00N/ANews CoverageAnalyst ForecastBDTXBlack Diamond Therapeutics3.4735 of 5 stars$3.72-1.8%$11.00+195.7%+6.8%$211.80M$70M16.1790News CoveragePositive NewsAnalyst Forecast Related Companies and Tools Related Companies Heron Therapeutics Competitors Atea Pharmaceuticals Competitors Tiziana Life Sciences Competitors ProQR Therapeutics Competitors Sagimet Biosciences Competitors Enanta Pharmaceuticals Competitors Entrada Therapeutics Competitors Eupraxia Pharmaceuticals Competitors BioAge Labs Competitors Black Diamond Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMX) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredMelt-up warning America’s $37.5 trillion debt spiral, soaring deficits, and repeated credit downgrades are exactly what Porter...Porter & Company | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
